1. Introduction {#sec1}
===============

Military service members (SM) deployed to wars in Iraq and Afghanistan are more likely to experience posttraumatic stress disorder (PTSD) symptoms related to both warzone and homefront experiences ([@bib37], [@bib43]) than those who did not deploy. Post-deployment PTSD symptoms are associated with reduced quality of life and functional status in SMs ([@bib34], [@bib42]), even for those whose symptoms fall short of meeting full diagnostic criteria for PTSD ([@bib3], [@bib10], [@bib19]). The current literature implies a variable risk for PTSD symptom development, attributable to a number of risk (e.g. number of deployments, traumatic brain injury, combat exposure, genetics) and resilience (e.g. unit support, post-deployment social support) factors ([@bib12], [@bib26], [@bib30], [@bib35], [@bib36]). However, less attention has been given to physiological factors that may signal risk for symptom progression, or conversely, the potential for resilience, after deployment, particularly with respect to subthreshold PTSD.

The catecholamines dopamine (DA), epinephrine (EPI), and norepinephrine (NE) are monoamines that are produced both within the central nervous system, where they act as neurotransmitters that are released to facilitate adaptive responses to acute stressors ([@bib1], [@bib38]), as well as in the sympathoadrenal system where they regulate physiologic responses to stressors. While beneficial in acute stress, repeated activation in chronic stress leads to dysregulation of catecholamine release, and increases the risk of PTSD; whereas adaptive catecholamine responses may signal resilience ([@bib18]). Precipitating events and psychological responses may dictate physiological reactions, but physiological reactions may also lead to psychological effects. Basal catecholamine levels have been associated with PTSD in a community sample ([@bib44]), and there is some evidence that neuroendocrine measures (e.g. cortisol and NE) may be linked with trauma-related symptoms in adults within two months after trauma ([@bib5]). Findings also indicate that catecholamine elevations can persist longer than 6 months given psychopathology. For example, combat veterans with chronic PTSD have higher baseline cerebral spinal fluid NE concentrations under unstressed conditions than their counterparts without PTSD ([@bib8]). Furthermore, recent work suggests that variants of the gene coding for catechol-O-methyl transferase, an enzyme involved in catecholamine metabolism, are associated with PTSD ([@bib17], [@bib23]).

Building upon these studies, we hypothesized that basal catecholamine levels obtained shortly after return from deployment could further improve our ability to predict resilience against combat-related PTSD symptoms in the subsequent months. We therefore compared catecholamine levels obtained within two months after return from deployment (T1) with PTSD symptoms three months later (T2). We expected that lower levels of DA, EPI, and NE at T1 would be associated with less severe PTSD symptoms at T2. Given that psychological states can induce changes in catecholamine systems, we also examined the reverse relationship, anticipating that lower T1 PTSD symptoms would be associated with lower catecholamine levels at T2.

2. Methods {#sec2}
==========

2.1. Participants and procedure {#sec2.1}
-------------------------------

SMs (N = 87) were recruited either through institutional review board-approved advertisements, or via direct contact immediately upon their return to the U.S. during postdeployment demobilization procedures at Fort Dix, NJ. Their current duty stations spanned the United States. They completed a T1 assessment within two months of return from deployment to Iraq or Afghanistan and then again three months later (T2). Inclusion criteria included the ability to complete informed consent, a structured interview, and a morning blood draw. Participants screening positive for probable PTSD (PTSD Checklist score ≥ 50), major depression (Patient Health Questionnaire-9 score ≥ 10), or post-concussive syndrome at baseline were excluded. Further exclusionary criteria included having a history of head injury resulting in a loss of consciousness for 60 minutes or more, a current Glasgow Coma Scale of less than 14 points, active psychotic symptoms, or active suicidal or homicidal ideation. Participants on alpha blockers or calcium channel blockers were excluded if they were unable to hold these medications for a 24-hour period preceding brain imaging scans. Combat-related PTSD symptoms were assessed by a trained, PhD-level psychologist using the Clinician-Administered PTSD Scale for DSM-IV (CAPS, [@bib46], [@bib47]), with traumatic events including improvised explosive devices, firefight, vehicular accidents, and other combat-related traumas. The frequency and intensity of each symptom cluster (e.g. re-experiencing, avoidance, hyperarousal) were combined to create a total score.

Blood draws occurred prior to 0900. Plasma samples were isolated from whole blood in sodium heparin preserved collection tubes with centrifugation for 10 minutes at room temperature. Samples were stored at −70 °C and run in a single batch. A commercially available Enzyme Immunoassay measured plasma catecholamine (EPI, NE, DA) levels, using Alpco Diagnostics (Salem, NH) Tri-Cat assay (17-TCTHUE03-RES).

2.2. Data analysis {#sec2.2}
------------------

First, step-wise linear regressions assessed whether T1 catecholamine levels were associated with T2 CAPS scores. Age, gender, and T1 CAPS score served as control variables. Catecholamine levels (DA, EPI, and NE) were entered as independent predictors. Both controls and predictors were entered in a step-wise fashion. The corresponding T2 CAPS score was analyzed as the dependent variable. T2 analyses modeled CAPS frequency and intensity, and CAPS symptom clusters, separately. Additional analyses were conducted to determine whether the reverse relationship was supported, such that T1 CAPS scores were associated with catecholamine levels at T2 when controlling for T1 catecholamine levels.

3. Results {#sec3}
==========

Reflecting the overall deployed population, study participants were predominantly male (85%), single (53%), Caucasian (73%), and employed (71%). On average, participants were 30.0 (SD = 8.0) years old, had served 9.4 (5.9) years in the military, and had been deployed 1.7 (SD = 1.0) times since 2001. Total CAPS scores decreased from T1 to T2. In particular, symptom frequency and re-experiencing symptoms showed significant decreases between time points. Catecholamine levels and CAPS scores are shown in [Table 1](#tbl1){ref-type="table"}. There were no significant correlations between T1 catecholamine levels and T1 CAPS scores. The correlations between T1 variables, as well the correlations among T1 and T2 variables, are shown in [Table 2](#tbl2){ref-type="table"}.

In order to examine the relationship between T1 catecholamines and PTSD symptomatology at T2, we completed step-wise linear regressions, while adjusting for T1 PTSD symptomatology. When controlling for T1 CAPS scores, step-wise linear regressions demonstrated that T1 NE was predictive of PTSD symptomatology at T2, in as much as T1 NE (β = .28, SE = .01, p = .03) was positively associated with T2 total CAPS scores (see [Fig. 1](#fig1){ref-type="fig"}). T2 step-wise linear regressions examined whether this association was due to symptom frequency or intensity. T1 NE levels (β = .32, SE = .004, p = .02) were associated with T2 CAPS intensity but not CAPS frequency. For these regressions, age, gender, and other catecholamines were not included in the final models as they were not significantly associated with T2 CAPS scores.

Next, step-wise linear regressions examined whether T1 catecholamine levels were associated with particular CAPS symptom clusters. T1 catecholamines were not associated with re-experiencing or hyperarousal at T2. However, T1 NE was positively associated with T2 avoidance scores (β = .38, SE = .004, p = .01). In particular, NE was positively associated with T2 avoidance frequency (β = .36, SE = .002, p = .006) and intensity (β = .38, SE = .002, p = .007). As noted in the previous step-wise regressions, age, gender, and other catecholamines were not retained in any of the final models.

Lastly, we completed T2 step-wise linear regressions to determine whether the reverse relationship was supported, such that T1 CAPS scores were associated with catecholamine levels at T2. In each of these analyses, the CAPS total score, frequency score, and intensity score were not associated with T2 catecholamine levels, when controlling for T1 catecholamine levels. When examining CAPS symptom clusters separately, T1 avoidance was associated with T2 DA levels (β = .40, SE = .63, p = .04).

4. Discussion {#sec4}
=============

We found that lower blood NE levels obtained within two months after return from deployment were associated with lower combat-related PTSD symptoms three months later. In particular, T1 NE was positively correlated with overall symptom intensity and avoidance symptoms at T2. Avoidance is most strongly associated with reduced functioning among SM deployed to Iraq and Afghanistan ([@bib31], [@bib33]), therefore identifying a biomarker of resilience may be especially important when developing treatments focused on promoting recovery after deployment.

Elevated NE activity has been associated with both PTSD ([@bib25]), and with enhancement of memory consolidation in emotionally arousing situations in those with PTSD ([@bib38]). Increased NE can also result in heightened arousal and nightmares in PTSD patients, and prazosin, a post-synaptic α1-adrenergic receptor antagonist, has been shown to be a successful therapy for this element of combat-related PTSD ([@bib29]). Other studies have found mixed results when assessing psychopharmacological NE interventions ([@bib39]). For example, propranolol, a β-adrenergic antagonists that blocks post-synaptic NE receptors, has not been shown to reduce PTSD symptoms or the likelihood of a PTSD diagnosis when administered acutely after traumatic events ([@bib13], [@bib40]) Furthermore, clonidine, a α2-adrenergic receptor agonist, has been shown to reduce hyperarousal symptoms among individuals who have comorbid PTSD and borderline personality disorder ([@bib45]); whereas guanfacine, an α2-adrenergic receptor agonist, has been shown to have no effect on chronic PTSD among veterans ([@bib21]). The difference between the two studies\' findings may be due to participant characteristics, comorbidities, sample sizes, or the medications themselves, despite having similar functioning. Our results are consistent with previous findings showing that NE and cortisol levels, measured acutely after trauma, are predictive of subsequent PTSD symptoms ([@bib5]). Interestingly, a study involving treatment for complicated grief also found that individuals with lower basal NE levels had the lowest post-therapy complicated grief symptoms, even when controlling for T1 symptoms ([@bib24]).

We found evidence that T1 PTSD symptoms are associated with subsequent catecholamine levels three months later. Lower T1 avoidance scores were associated with reductions in DA at T2. Dopaminergic systems have been associated with avoidance learning ([@bib7]), whereas administration of a dopamine agonist (pramipexole) has been shown to diminish reinforcement-related behaviors in healthy participants ([@bib27]). In the present findings, successful avoidance of trauma-related stimuli may enable avoidance learning. Across time, the act of avoidance may become physiologically reinforcing, even if an immediate perceived threat is not present. Historically, animal studies demonstrate the role of NE in avoidance. In the amygdala, NE increases during unconditioned stress ([@bib11], [@bib41]), which in turn is associated with enhanced avoidance learning retention and avoidance behaviors in rats ([@bib9], [@bib41]). Taken together, the present findings demonstrate a bidirectional relationship between symptomology and physiology, an improved understanding of which may help identify individuals who experience sub-threshold combat-related PTSD symptoms in the months following return from deployment.

The present study possesses a number of strengths including the use of longitudinal data, analyses assessing for bi-directional relationships between variables, and exploration of individual symptom clusters, which may facilitate the development of novel therapies ([@bib22]). Exploration of the biological underpinnings of symptom severity has been highly advocated by the National Institutes of Health ([@bib16]). The current study provides markers of resilience that are independent of DSM diagnostic criteria. Moreover, our timeline focused on the acute post-deployment period, a window of time which can set the course for future combat-related PTSD symptoms, and provides the potential for early intervention.

There are also some limitations to be acknowledged. The time course of combat-related PTSD symptoms may follow a variety of trajectories which may not be captured by only assessing two points in time. Second, we cannot rule out common precursors or mediating factors that may serve to link PTSD symptoms and catecholamine function and future studies would benefit from the addition of a non-deployed control group to determine the unique contributions of combat-related trauma in the relationship between symptoms and catecholamine function. Third, although our first time point is shortly after deployment, the deployment experience is highly variable, and some may have experienced significant traumas early in their deployment, so that nearly a year may have already passed by this point for some individuals. Fourth, we did not exclude individuals taking psychotropic medications that may affect catecholamine levels, future research would benefit from expanding and stratifying individuals by medication. Finally, in deliberately focusing on a sample with subthreshold symptoms, we may be elucidating patterns predictive of recovery more so than PTSD.

Risk stratification is the first step toward reducing PTSD symptoms in SMs who have been deployed. Recent evidence suggests early evidence-based intervention after a trauma may reduce the adverse effect of biological risk factors ([@bib32]). Within a clinical context, biological markers help elucidate a more detailed profile of functioning and help fill in gaps where self-report accuracy declines in the face of recall bias, symptom minimization, and alexithymia. As such, these markers could be used to identify those in need of more intense treatment or resiliency training prior to meeting clinical criteria for PTSD, thereby preventing progression to a PTSD diagnosis.
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###### 

Total, intensity, frequency, and cluster CAPS scores across time points.

                            T1 mean (SD)      T2 mean (SD)      *t* (*p*)
  ------------------------- ----------------- ----------------- -------------
  Dopamine                  28.64 (16.05)     28.67 (16.03)     .26 (.79)
  Epinephrine               51.20 (25.57)     61.01 (36.43)     1.44 (.16)
  Norepinephrine            274.77 (173.50)   309.67 (215.32)   1.18 (.25)
  Total CAPS                19.6 (12.8)       15.4 (15.1)       2.32 (.02)
  CAPS -- intensity         7.7 (5.4)         6.1 (6.04)        1.99 (.05)
  CAPS -- frequency         12.0 (7.6)        9.1 (9.0)         2.56 (.01)
  CAPS -- re-experiencing   4.3 (4.3)         2.02 (3.7)        3.65 (.001)
  CAPS -- avoidance         4.9 (4.94)        4.4 (6.5)         .62 (.54)
  CAPS -- hyperarousal      10.5 (6.4)        8.9 (7.5)         1.65 (.11)

Note: CAPS: Clinician Administered PTSD Scale.

###### 

Correlations among catecholamine levels and PTSD symptoms, with correlations among T1 variables shown below the diagonal and correlations between T1 with T2 variables shown above the diagonal.

                             1\.      2\.     3\.    4\.       5\.       6\.       7\.       8\.       9\.
  -------------------------- -------- ------- ------ --------- --------- --------- --------- --------- ---------
  1\. Dopamine                        .19     −.02   .02       −.02      .04       −.04      .07       −.004
  2\. Epinephrine            .001             .05    .24       .26       .22       .07       .29\*     .20
  3\. Norepinephrine         .08      .24\*          .13       .18       .10       −.06      .19       .13
  4\. Total CAPS             −.001    .07     −.18             .46\*\*   .52\*\*   .32\*     .32\*     .59\*\*
  5\. CAPS -- intensity      .04      .10     −.17   .98\*\*             .49\*\*   .27\*\*   .31\*     .56\*\*
  6\. CAPS -- frequency      .04      .07     −.19   .98\*\*   .93\*\*             .25       .08       .40\*\*
  7\. CAPS -- re-exper.      −.24\*   −.04    −.12   .80\*\*   .78\*\*   .79\*\*             .44\*\*   .37\*\*
  8\. CAPS -- avoidance      .26\*    .09     −.16   .74\*\*   .74\*\*   .71\*\*   .38\*\*             .59\*\*
  9\. CAPS -- hyperarousal   −.04     .10     −.15   .89\*\*   .85\*\*   .89\*\*   .63\*\*   .45\*\*   

Note: CAPS = Clinician Administered PTSD Scale, re-exper. = re-experiencing.

\*\*p \< .01, \*p \< .05.
